Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns
Clinical Infectious Diseases · 2023
DOI: 10.1093/cid/ciad248 ↗Kurz gefasst
Kommentar in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Naomi E Aronson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA. Hauptthemen laut MEDLINE: Leishmania braziliensis, Leishmaniasis, Cutaneous, Antiprotozoal Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Division, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- Division of Dermatology, University of Toronto, Toronto, Ontario, Canada.
Zitieren
APA
Aronson, N. E., & Billick, K. (2023). Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad248
Vancouver
Aronson NE, Billick K. Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciad248
BibTeX
@article{Aronson2023,
author = {Aronson, Naomi E and Billick, Kendall},
title = {Intralesional Antimonial Drug Treatment for Leishmania braziliensis Cutaneous Leishmaniasis: The Knowns and the Unknowns},
journal = {Clinical Infectious Diseases},
year = {2023},
doi = {10.1093/cid/ciad248}
}
EUVIMED